Home LiteratureArticle Details
PMID: 21514250 Published · ppublish English Consensus Development Conference, NIH Journal Article Research Support, Non-U.S. Gov't

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association ·Vol. 7 ·No. 3 ·2011-05-00 ·Pages 263-9

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH

Abstract

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.

MeSH Terms
Alzheimer Disease/diagnosis,physiopathology,psychology Biomarkers/cerebrospinal fluid Diagnosis, Differential Diagnostic Imaging/standards Disease Progression Humans National Institute on Aging (U.S.)/standards Practice Guidelines as Topic/standards Societies, Medical/standards United States
Chemicals
Biomarkers
Authors & Affiliations
18 authors, click to expand affiliations / ORCID
McKhann Guy M
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. guy.mckhann@jhu.edu
Knopman David S
Chertkow Howard
Hyman Bradley T
Jack Clifford R
Kawas Claudia H
Klunk William E
Koroshetz Walter J
Manly Jennifer J
Mayeux Richard
Mohs Richard C
Morris John C
Rossor Martin N
Scheltens Philip
Carrillo Maria C
Thies Bill
Weintraub Sandra
Phelps Creighton H
References (24)
24 references, click to expand
  1. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.
    Ann Neurol. 2008 Oct;64(4):388-401 PMID: 18991338
  2. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.
    Neurology. 1998 Dec;51(6):1546-54 PMID: 9855500
  3. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.
    Neurology. 1993 Feb;43(2):250-60 PMID: 8094895
  4. Classification of primary progressive aphasia and its variants.
    Neurology. 2011 Mar 15;76(11):1006-14 PMID: 21325651
  5. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Neurology. 2001 May 8;56(9):1143-53 PMID: 11342678
  6. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations.
    Am J Geriatr Psychiatry. 2004 Mar-Apr;12(2):146-56 PMID: 15010344
  7. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
    Neurology. 2005 Dec 27;65(12):1863-72 PMID: 16237129
  8. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.
    Ann Neurol. 2009 Feb;65(2):176-83 PMID: 19260027
  9. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
    Lancet Neurol. 2010 Jan;9(1):119-28 PMID: 20083042
  10. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions.
    Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):S14-8 PMID: 18090417
  11. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement. 2011 May;7(3):280-92 PMID: 21514248
  12. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Alzheimers Dement. 2008 Jan;4(1):38-48 PMID: 18631949
  13. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.
    J Neuropathol Exp Neurol. 1997 Oct;56(10):1095-7 PMID: 9329452
  14. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.
    N Engl J Med. 1998 Feb 19;338(8):506-11 PMID: 9468467
  15. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement. 2011 May;7(3):270-9 PMID: 21514249
  16. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
    Lancet Neurol. 2007 Aug;6(8):734-46 PMID: 17616482
  17. Focal cortical presentations of Alzheimer's disease.
    Brain. 2007 Oct;130(Pt 10):2636-45 PMID: 17898010
  18. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Brain. 2008 Mar;131(Pt 3):665-80 PMID: 18263627
  19. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement. 2011 May;7(3):257-62 PMID: 21514247
  20. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.
    Ann Neurol. 2010 Mar;67(3):317-24 PMID: 20373343
  21. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.
    Arch Neurol. 2001 Nov;58(11):1803-9 PMID: 11708987
  22. Age, Alzheimer's disease and dementia in the Baltimore Longitudinal Study of Ageing.
    Brain. 2010 Aug;133(Pt 8):2225-31 PMID: 20647264
  23. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.
    Nat Rev Neurosci. 2008 Oct;9(10):768-78 PMID: 18802446
  24. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
Article Info
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
Abbr.
Alzheimers Dement
ISSN
1552-5279
Published
2011-05-00
Epub
2011-00-21
Pages
263-9
Language
English
Region
United States
NLM ID
101231978
PMCID
PMC3312024
Subset
IM
Grants
NIA NIH HHS · P50 AG005146 · United States
NIA NIH HHS · P50 AG005146-28 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com